Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Defence Therapeutics

Main (gene editing) focus: Novel methods for delivery of gene-editing systems

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:DTCFF)

Location: Vancouver, British Columbia, Canada

Website: https://defencetherapeutics.com/

Defence Therapeutics develops a proprietary platform called ACCUM^TM, which enables precision delivery of vaccine antigens or drugs to target cells. The company recently announced strong in vitro results for the delivery of the CRISPR-Cas9 system using ACCUM^TM technology. The company now seeks collaborations in the gene-editing space.

Defence Therapeutics

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Defence Therapeutics

Search CRISPR Medicine